Search research articles
Contact Us
Filters
Showing results (111-120 of 125) with videos related to
Page
of 13
Sort By:
The Lancet. Haematology
|
May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
Benjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel
Eric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Blood Cancer Discovery
|
October 15, 2021
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
Malin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.
Nature Genetics
|
August 20, 2025
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
Francesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Blood Cancer Journal
|
September 19, 2024
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
Malin Hultcrantz, Hani Hassoun, Neha Korde, et al.
Biorxiv : the Preprint Server for Biology
|
September 16, 2024
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma
Francesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
American Journal of Hematology
|
April 26, 2022
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience
Meera Mohan, Melody Renee Becnel, Urvi A Shah, et al.
JAMA Oncology
|
September 16, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial
Dickran Kazandjian, Elizabeth Hill, Alexander Dew, et al.
Nature Cancer
|
November 9, 2023
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Francesco Maura, Eileen M Boyle, David Coffey, et al.
Blood Cancer Discovery
|
June 12, 2026
Genomic features do not account for differences in multiple myeloma risk by ancestry
Kylee H Maclachlan, Marios Papadimitriou, Patrick Blaney, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 125) with videos related to
Sort By:
Page
of 13
The Lancet. Haematology
|
May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
Benjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel
Eric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Blood Cancer Discovery
|
October 15, 2021
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
Malin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.
Nature Genetics
|
August 20, 2025
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
Francesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Blood Cancer Journal
|
September 19, 2024
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
Malin Hultcrantz, Hani Hassoun, Neha Korde, et al.
Biorxiv : the Preprint Server for Biology
|
September 16, 2024
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma
Francesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
American Journal of Hematology
|
April 26, 2022
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience
Meera Mohan, Melody Renee Becnel, Urvi A Shah, et al.
JAMA Oncology
|
September 16, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial
Dickran Kazandjian, Elizabeth Hill, Alexander Dew, et al.
Nature Cancer
|
November 9, 2023
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Francesco Maura, Eileen M Boyle, David Coffey, et al.
Blood Cancer Discovery
|
June 12, 2026
Genomic features do not account for differences in multiple myeloma risk by ancestry
Kylee H Maclachlan, Marios Papadimitriou, Patrick Blaney, et al.
Page
of 13